Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, et al.

Antimicrob Agents Chemother. 1993 May;37(5):1095-101.

2.

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.

Montaner JS, Singer J, Schechter MT, Raboud JM, Tsoukas C, O'Shaughnessy M, Ruedy J, Nagai K, Salomon H, Spira B, et al.

AIDS. 1993 Feb;7(2):189-96.

PMID:
8466681
3.

Study of human immunodeficiency virus resistance to 2'-3'-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy.

Dimitrov DH, Hollinger FB, Baker CJ, Kline MW, Doyle M, Bremer JW, Shearer WT.

J Infect Dis. 1993 Apr;167(4):818-23.

PMID:
8450246
4.
5.

Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.

Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.

Antiviral Res. 1993 Apr;20(4):267-77.

PMID:
8097906
6.

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC.

J Infect Dis. 1993 Mar;167(3):526-32.

PMID:
7680058
7.

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao XJ, Fanning M, Montaner JS, O'Shaughnessy M, Gelmon K, Tsoukas C, et al.

AIDS. 1989 Jul;3(7):411-5.

PMID:
2504243
8.
9.

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Larder BA, Darby G, Richman DD.

Science. 1989 Mar 31;243(4899):1731-4.

PMID:
2467383
11.

Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

Land S, Terloar G, McPhee D, Birch C, Doherty R, Cooper D, Gust I.

J Infect Dis. 1990 Feb;161(2):326-9.

PMID:
2299212
12.
13.

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

Richman DD, Grimes JM, Lagakos SW.

J Acquir Immune Defic Syndr. 1990;3(8):743-6.

PMID:
2114476
14.

In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy.

Fitzgibbon JE, Howell RM, Schwartzer TA, Gocke DJ, Dubin DT.

AIDS Res Hum Retroviruses. 1991 Mar;7(3):265-9.

PMID:
2064825
15.

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, Darby G, Goudsmit J, Larder BA.

Lancet. 1990 Sep 8;336(8715):585-90.

PMID:
1975378
17.

Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.

Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T.

J Infect Dis. 1991 Dec;164(6):1075-81.

PMID:
1720152
18.

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.

Science. 1991 Sep 27;253(5027):1557-9.

PMID:
1716788
19.
20.

Supplemental Content

Support Center